Aggregated Tau activates NLRP3–ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo

Abstract

Brains of Alzheimer’s disease patients are characterized by the presence of amyloid plaques and neurofibrillary tangles, both invariably associated with neuroinflammation. A crucial role for NLRP3–ASC inflammasome [NACHT, LRR and PYD domains-containing protein 3 (NLRP3)–Apoptosis-associated speck-like protein containing a CARD (ASC)] in amyloid-beta (Aβ)-induced microgliosis and Aβ pathology has been unequivocally identified. Aβ aggregates activate NLRP3–ASC inflammasome (Halle et al. in Nat Immunol 9:857–865, 2008) and conversely NLRP3–ASC inflammasome activation exacerbates amyloid pathology in vivo (Heneka et al. in Nature 493:674–678, 2013), including by prion-like ASC-speck cross-seeding (Venegas et al. in Nature 552:355–361, 2017). However, the link between inflammasome activation, as crucial sensor of innate immunity, and Tau remains unexplored. Here, we analyzed whether Tau aggregates acting as prion-like Tau seeds can activate NLRP3–ASC inflammasome. We demonstrate that Tau seeds activate NLRP3–ASC-dependent inflammasome in primary microglia, following microglial uptake and lysosomal sorting of Tau seeds. Next, we analyzed the role of inflammasome activation in prion-like or templated seeding of Tau pathology and found significant inhibition of exogenously seeded Tau pathology by ASC deficiency in Tau transgenic mice. We furthermore demonstrate that chronic intracerebral administration of the NLRP3 inhibitor, MCC950, inhibits exogenously seeded Tau pathology. Finally, ASC deficiency also decreased non-exogenously seeded Tau pathology in Tau transgenic mice. Overall our findings demonstrate that Tau-seeding competent, aggregated Tau activates the ASC inflammasome through the NLRP3–ASC axis, and we demonstrate an exacerbating role of the NLRP3–ASC axis on exogenously and non-exogenously seeded Tau pathology in Tau mice in vivo. The NLRP3–ASC inflammasome, which is an important sensor of innate immunity and intensively explored for its role in health and disease, hence presents as an interesting therapeutic approach to target three crucial pathogenetic processes in AD, including prion-like seeding of Tau pathology, Aβ pathology and neuroinflammation.Electronic supplementary materialThe online version of this article (10.1007/s00401-018-01957-y) contains supplementary material, which is available to authorized users.

Meisoindigo Protects Against Focal Cerebral Ischemia-Reperfusion Injury by Inhibiting NLRP3 Inflammasome Activation and Regulating Microglia/Macrophage Polarization via TLR4/NF-κB Signaling Pathway

“…Meisoindigo reduced brain water content and significantly downregulated the expression of AQP4 compared with the vehicle group (P < 0.05) (Figure 2). MCC950, a highly potent and selective inhibitor of the NLRP3 inflammasome, in vitro and in vivo (Ren et al, 2018;Stancu et al, 2019), had effects similar to those of meisoindigo.…”

Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines

“…Phagocytosed tau can be released in exosomes to promote tau propagation in adjacent cells [78]. Tau aggregates like prions and the aggregated tau activates the nod-like receptors P3-apoptosis-associated speck-like protein containing caspase activation and recruitment domains (CARD) (ASC) inflammasome, one of the sensors important for activation of innate immune response [79]. Early microglial activation and central and peripheral inflammation were detected in patients with dementia with LBs [80].…”

Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease

“…Bot deletion of tau and hyperphosphorylation of tau impair insulin signaling (Marciniak et al, 2017;Rodriguez-Rodriguez et al, 2017). Tau can also induce inflammasome activation in the brain, which may further contribute to increased reactive oxygen species (ROS) and impaired insulin signaling (Ising et al, 2019;Stancu et al, 2019). Thus, it appears that the Aβ and tau proteins likely have a shared role in causing dysregulated insulin signaling in the brain.…”